Navigation Links
Senetek PLC Announces 2009 Annual General Meeting Voting Results

NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that shareholders had approved all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held on December 14, 2009. Voting results were as follows:

    Description of            Votes        Votes         Votes         Non-
     Matter                    For        Against       Withheld      Votes
    --------------            -----       -------       --------      -----

    Election of  Kerry
     Dukes as Director      6,165,331    1,363,208       71,963      45,300
    Receipt of Annual
     Accounts for 2008
     with Directors'
     Report, auditors'
     report on those
     accounts and
     approve the last
     report                 6,717,147      795,815       87,540      45,300
    Appointment of
     Macias Gini &
     O'Connell LLP and
     BDO Stoy Hayward
     as the Company's
     auditors for 2009      6,663,843      796,173      140,486      45,300

"We are pleased with the results of the voting and we thank our shareholders for their support" stated Frank J. Massino, Senetek Chairman and CEO.

Senetek PLC recently announced the hiring of Miller Tabak + Co., LLC as financial and strategic advisors. The Board has retained the firm to evaluate the Company's technology and business model and to make recommendations on the development of a plan that will benefit shareholders. As a result of this evaluation, Miller Tabak has made the following recommendations:

  • Consider changing the focus and direction of the Company and the current business model;
  • Identify potential business partners for merger and/or acquisition;
  • Raise additional capital.

The Company is currently in discussions with multiple investors and potential partners, however there is no assurance that these discussions will result in a completed transaction.

About Senetek PLC: Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology, most recently resulting in the development of kinetin, the active ingredient in the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites --, and -- or call 877-SENETEK (United States and Canada) or 707-259-6278 (International Locations).

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Implements New Corporate Communication Policy
2. Senetek PLC Reports Second Quarter 2009 Financial Results
3. Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany
4. Senetek PLC Reports First Quarter 2009 Financial Results
5. Senetek PLC Reports 2008 Financial Results
6. Dynamics Group AG Publishes Research Report on Senetek
7. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
8. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
9. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
10. Senetek PLC Announces Key Personnel Appointments
11. Senetek PLC Reports 2007 Financial Results
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: